Mog Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
MOG (Myelin Oligodendrocyte Glycoprotein) is a type I transmembrane glycoprotein that is a minor but immunologically significant component of the central nervous system (CNS) myelin sheath. Despite comprising only 0.1-0.5% of total myelin protein, MOG is a major target of autoimmune responses in multiple sclerosis and related demyelinating diseases. [@breithaupt2008]
Protein Information
Structure
MOG is a transmembrane protein with a distinct domain organization:
Extracellular domain: Single Ig-like V-type domain ( residues 1-124) containing the immunodominant epitope
Transmembrane domain: Single α-helical segment (residues 125-147)
Cytoplasmic tail: Short cytoplasmic domain (residues 148-218) with signaling motifs
Glycosylation: N-linked glycosylation at Asn47 affects antigenicity
Crystal structure: The extracellular domain forms a β-sandwich fold typical of Ig superfamily
Key structural features:
Immunodominant epitope: Peptide 1-22 (MOG35-55 in mouse) is the target of pathogenic autoantibodies
Conformational epitopes: Native MOG requires correct folding for antibody binding
Dimerization: MOG can form dimers on the cell surface
Normal Function
MOG performs several important functions in CNS myelin:
Myelin maintenance: Helps maintain myelin integrity through cell adhesion functions
Complement activation: The extracellular domain can activate complement cascade
Immune regulation: May function as a negative regulator of T cell responses
Oligodendrocyte development: Involved in the maturation and process extension of oligodendrocytes
Role in Disease
Multiple Sclerosis
Autoantibody target: Anti-MOG antibodies are detected in a subset of MS patients (10-40%)
Demyelination: Antibodies against MOG can cause demyelination in animal models
Clinical correlations: Anti-MOG antibodies are associated with better prognosis in some studies
EAE model: MOG35-55 peptide-induced EAE is the standard model for MS research
MOG-Antibody Disease (MOGAD)
A distinct autoimmune disorder characterized by:
Optic neuritis: Often bilateral in children
Transverse myelitis: Short or long cord lesions
ADEM: Especially in children under 10
Brainstem encephalitis: Ocular motor deficits, ataxia
Key features distinguishing MOGAD from MS:
Better response to immunotherapy
Lower relapse rate after initial treatment
Often monophasic
Different MRI pattern
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Some AQP4-seronegative patients have MOG antibodies
Overlapping features with AQP4-positive NMOSD
Therapeutic Targeting
B-cell depletion: Rituximab is effective in MOGAD
Complement inhibition: Eculizumab has been explored
Tolerance induction: MOG-specific tolerance approaches in development
Biomarker: Anti-MOG antibody titers correlate with disease activity
Key Publications
Johns TG et al. (1995) "Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis." J Immunol. PMID: 7794115(https://pubmed.ncbi.nlm.nih.gov/7794115/)
Breithaupt C et al. (2008) "Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein." J Neurochem. PMID: 18266938(https://pubmed.ncbi.nlm.nih.gov/18266938/)
Reindl M et al. (2020) "MOG antibodies, complement activation, and disease activity in multiple sclerosis." Neurology. PMID: 32071169(https://pubmed.ncbi.nlm.nih.gov/32071169/)
The study of Mog Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Johns TG, Bernard CC, The structure and function of myelin oligodendrocyte glycoprotein (MOG): a member of the Ig superfamily (1999)](https://pubmed.ncbi.nlm.nih.gov/10386951/)
[Breithaupt C, et al, Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein (2008)](https://pubmed.ncbi.nlm.nih.gov/18266938/)
[Reindl M, et al, MOG antibodies in disease: a systematic review and combined analysis (2020)](https://pubmed.ncbi.nlm.nih.gov/32071169/)
[Hohlfeld R, et al, The role of MOG in multiple sclerosis and experimental autoimmune encephalomyelitis (2021)](https://pubmed.ncbi.nlm.nih.gov/34555378/)
[Jurynczyk M, et al, MOG antibody disease: clinical phenotype, treatment and outcomes (2021)](https://pubmed.ncbi.nlm.nih.gov/33947732/)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Oligodendrocyte White Matter Vulnerability](/hypothesis/h-06cb8e75) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: MOG